Comprehensive Testing for Constitutional/Mosaic Mutations with Deep Coverage via NGS

Similar documents
Comprehensive Testing for Constitutional/Mosaic Mutations with Deep Coverage via NGS

Comprehensive Testing for Constitutional/Mosaic Mutations with Deep Coverage via NGS

Prices listed correspond to institutional rates only; please contact the lab for insurance rates.

Prices listed correspond to institutional rates only; please contact the lab for insurance rates.

Prices listed correspond to institutional rates only; please contact the lab for insurance rates.

Accession: Additional testing information is available at

Test Requisition Form

Accession: Additional testing information is available at

MEDICAL GENOMICS LABORATORY. Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG)

MEDICAL GENOMICS LABORATORY. Non-NF1 RASopathy panel by Next-Gen Sequencing and Deletion/Duplication Analysis of SPRED1 (NNP-NG)

MEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)

Billing Information:

Comprehensive Testing for neurofibromatoses, RASopathies, and tuberous sclerosis at UAB

Neurofibromatosis type 1 and RASopathies

Russell-Silver syndrome (RSS)

MRC-Holland MLPA. Description version 30; 06 June 2017

MRC-Holland MLPA. Description version 29; 31 July 2015

Get a more complete picture into your patient's pregnancy with PreSeek

MRC-Holland MLPA. Description version 08; 30 March 2015

NGS in tissue and liquid biopsy

Genetic causes 90% Other causes 10% No variants are found in known genes associated with ADPKD

The Center for PERSONALIZED DIAGNOSTICS

Insights from Sequencing the Melanoma Exome

NGS for Cancer Predisposition

Variant interpretation using the ACMG-AMP guidelines

Date of Birth Gender Ethnicity/Family History Male Female Unknown. (Institutional Billing only. We DO NOT bill patients directly.)

Accel-Amplicon Panels

CANCER GENETICS PROVIDER SURVEY

GENETIC TESTING FOR NEUROFIBROMATOSIS

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Select analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie

Corporate Medical Policy

List the conditions known as neurophakomatosis and demonstrate their clinical findings:

UNIVERSITY OF PENNSYLVANIA GENETIC DIAGNOSTIC LABORATORY

Karl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz

Genomic Medicine: What every pathologist needs to know

MOLECULAR DIAGNOSIS for X-LINKED INTELLECTUAL DISABILITY

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

Fluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS

National Haemoglobinopathy Reference Laboratory. Information for Users

IMMEDIATE HOT LINE: Effective January 6, 2014

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R

Update on Genetic Testing for Melanoma

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION

IntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.

Benefits and pitfalls of new genetic tests

Familial Brain Tumour Syndromes

5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff

Neurocutaneous Syndromes. Phakomatoses

MET skipping mutation, EGFR

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Test Information Sheet

UNIVERSITY OF PENNSYLVANIA GENETIC DIAGNOSTIC LABORATORY. Name of Test Turnaround Time Cost CPT codes

MRC-Holland MLPA. Description version 08; 18 November 2016

TGL clinical User Guide

Original Policy Date

MRC-Holland MLPA. Description version 12; 13 January 2017

Renal Cystic Disease. Dr H Bierman

Comprehensive Test Menu August 2018

Importance of Clinical Information for Optimal Genetic Test Selection and Interpretation

No mutations were identified.

SALSA MLPA probemix P372-B1 Microdeletion Syndromes 6 Lot B1-1016, B

SureSelect Cancer All-In-One Custom and Catalog NGS Assays

Imaging in neurofibromatosis type 1: An original research article with focus on spinal lesions

Testing for Fabry Disease. What You Need to Know

Liquid biopsy in lung cancer: The EGFR paradigm

Plexiform Tumor of the Orbit

CHROMOSOMAL MICROARRAY (CGH+SNP)

BRCA 1/2. Breast cancer testing THINK ABOUT TOMORROW, TODAY

Division of Genomic Diagnostics CANCER GENOMIC TEST REQUISITION Page 1 of 6

MRC-Holland MLPA. Description version 08; 07 May 2015

Clinical Grade Genomic Profiling: The Time Has Come

TITLE: Genetic and Epigenetic Differences in Monozygotic Twins with NF1

Comprehensive Test Menu December 2018

The first non-invasive prenatal test that screens for single-gene disorders

TumorNext-HRD with OvaNext: Paired Germline and Tumor Analyses of Genes Involved in

MRC-Holland MLPA. Description version 06; 23 December 2016

Genetics and Genetic Testing for Autism:

TITLE: Interchromosomal Associations that Alter Nf1 Gene Expression can Modify Clinical Manifestations of Neurofibromatosis 1

A review of craniofacial and dental findings of the RASopathies

New Drug development and Personalized Therapy in The Era of Molecular Medicine

MRC-Holland MLPA. Description version 18; 09 September 2015

Test Information Sheet

MRC-Holland MLPA. Description version 06; 07 August 2015

LIST OF INVESTIGATIONS

TECHNICAL NOTICE. The CPT coding in this notice is effective January 1, 2013 and replaces the coding currently in use for these assays

Laboratory Service Report

Cancer Validation in the 100,000 genomes project. Dr Shirley Henderson ACGS spring meeting 06/07/16

Identification of a novel duplication mutation in the VHL gene in a large Chinese family with Von Hippel-Lindau (VHL) syndrome

Whole Exome Sequencing (WES): Questions and Answers for Providers

CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi

PATIENT INFORMATION (Please Print or Place ID Label) Last Name First Name MI

SALSA MLPA probemix P185-C2 Intersex Lot C2-1015: As compared to the previous version C1 (lot C1-0611), the lengths of four probes have been adjusted.


Neurological Disorders

Neurogenetics Genetic Testing and Ethical Issues

patient guide BrainTumorNext genetic testing for hereditary brain tumors Because knowing your risk can mean early detection and prevention

MOLECULAR PATHOLOGY IN PRACTICE CASE-BASED APPROACH. BARBORA IZRAEL VLKOVÁ

Corporate Medical Policy

Introduction of an NGS gene panel into the Haemato-Oncology MPN service

Transcription:

Comprehensive Testing for Constitutional/Mosaic Mutations with Deep Coverage via NGS NF1/SPRED1 and Other RASopathy Related Conditions NF1 only NGS testing and copy number analysis for the NF1 gene (NF1 NG) This testing includes an average coverage of 1800x to allow for the identification of mosaicism as low as 8% of the alleles. In addition, novel mutations identified in the NF1 gene will be confirmed via RNA based analysis at no additional charge. RNAbased testing will also be provided to non founder, multigenerational families with classic NF1 at no additional charge if next generation sequencing is found negative. $1,000 NF1/SPRED1 NGS testing and copy number analysis for NF1 and SPRED1 (NFSP NG) This testing includes an average coverage of 1800x to allow for the identification of mosaicism as low as 8% of the alleles. In addition, free of charge testing maybe available in scenarios summarized for NF1 only above. $1,100 (x2) Noonan only NGS panel (NNP NG) This testing includes BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PPP1CB, PTPN11, RAF1, RASA2, RIT1, SHOC2, SOS1, SPRED1 and SOS2 as well as copy number $1,200 81442 analysis for the SPRED1 gene. An average coverage of 1800x will allow for the identification of mosaicism as low as 8% of the alleles RASopathy NGS panel (RAS NG) This testing includes BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NF1, NRAS, PPP1CB, PTPN11, RAF1, RASA2, RIT1, SHOC2, SOS1, SPRED1 and SOS2 as well as copy number analysis for the NF1 and SPRED1 gene. An average coverage of 1800x will allow for In addition, free of charge testing may be available in scenarios summarized for NF1 only above. $1,500 81442 (x2) Peripheral Nerve Sheath Tumor Testing Peripheral Nerve Sheath Tumor NGS panel (PNT NG) This testing includes KRAS, LZTR1, NF1, NF2, PTPN11, and SMARCB1 as well as copy number analysis for the LZTR1, NF1, NF2, and SMARCB1. An average coverage of 1800x will allow for $1,500 blood (x3)

NF2/Schwannomatosis/Meningiomatosis Panel Testing NF2 only NGS testing and copy number analysis for the NF2 gene (NF2 NG) NF2 testing on either blood or fresh/frozen tumor by NGS sequencing and deletion/duplication analysis by MLPA. This testing includes an average coverage of 1800x to allow for In addition, novel mutations identified in the NF2 gene will be confirmed via RNA based analysis at no additional charge. $800 blood Schwannomatoisis/Multiple Schwannomas NGS Panel (SCH NG) This testing includes LZTR1, NF2, and SMARCB1 by NGS as well as copy number analysis of LZTR1, NF2, and SMARCB1. An average coverage of 1800x will allow for $1,500 blood (x2) Meningiomatosis/Multiple Meningioma NGS Panel (MEN NG) This testing includes NF2, SMARCB1, SMARCE1, and SUFU by NGS as well as copy number analysis of NF2 and SMARCB1. An average coverage of 1800x will allow for $1,500 blood Rhabdoid Tumor Predisposition Syndrome Panel Testing Rhabdoid Tumor Predisposition NGS panel (RT NG) This testing includes analysis of SMARCB1 by NGS as well as copy number analysis. An $800 blood average coverage of 1800x will allow for the identification of mosaicism as low as 8% of the alleles. Capillary Malformation Arteriovenous Malformation Syndrome Panel Testing Capillary Malformation Arteriovenous Malformation NFS panel (RASA NG) This testing includes analysis of RASA1 by NGS as well as copy number analysis. An average coverage of 1800x will allow for the identification of mosaicism as low as 8% of the alleles. $800 blood Tuberous Sclerosis Complex Testing Tuberous Sclerosis Complex NGS panel (TSCP NG) Testing of TSC1 and TSC2 on either blood or fresh/frozen tumor by NGS sequencing and deletion/duplication analysis by MLPA. This testing includes an average coverage of 1800x to allow for $1,500 blood

Neurofibroma/CAL Spot Biopsies for Comprehensive Testing NF1/SPRED1 and Other RASopathy Panel Testing on Biopsided Samples NF1analysis on biopsied CALs, with reflex to SPRED1, if negative (NF14C) Comprehensive RNA/cDNA based NF1 sequencing and dosage (del/dup) analysis with reflexive DNA based SPRED1 sequencing and dosage (del/dup) analysis on cultured melanocytes from café au lait spots in affected body regions for possible segmental/mosaic NF1 and/or Legius syndrome cases with pigmentary findings only **Please note: it is required to contact the laboratory at 205 934 5562 or email medgenomics@uabmc.edu in advance of sending specimens for this testing option** $2600 (for NF1 only analysis) $3200 (For NF1 with SPRED1 reflex) 88233 (culture) (NF1) (SPRED1) (NF1) 81404 (SPRED1) 120 Dependent on size and quality of the tissue specimen received (1) 2 3 5mm punch biopsies from CAL spots. Special transport media required for shipping: contact us at 205 934 556 NF1 analysis on biopsided neurofibromas (NF14N) Comprehensive RNA/cDNA based NF1 sequencing and dosage (del/dup) analysis on cultured neural crest derived cells from neurofibromas from affected body regions for $2,600 possible segmental/mosaic NF1 cases. **Please note: it is required to contact the laboratory at 205 934 5562 or email medgenomics@uabmc.edu in advance of sending specimens for this testing option** Peripheral Nerve Sheath Tumor NGS panel (PNT NG) This testing includes KRAS, LZTR1, NF1, NF2, PTPN11, and SMARCB1 as well as copy number analysis for the LZTR1, NF1, NF2, and SMARCB1. An average coverage of 1800x will allow for NF2 only NGS testing and copy number analysis for the NF2 gene (NF2 NG) NF2 testing on fresh/frozen tumor by NGS sequencing and deletion/duplication analysis by MLPA. This testing includes an average coverage of 1800x to allow for the identification of mosaicism as low as 8% of the alleles. In addition, novel mutations identified in the NF2 gene will be confirmed via RNA based analysis at no additional charge. $2,500 tumor 88233 (culture) Fresh/Frozen Tumor Based Comprehensive Testing Peripheral Nerve Sheath Tumor Testing on Fresh/Frozen Tumor $1,500 tumor 120 (x3) NF2/Schwannomatosis/Meningiomatosis Panel Testing On Fresh/Frozen Tumor Dependent on size and quality of the tissue specimen received (1) minimum 2 separate fresh neurofibromas. Special transport media required for shipping: contact us at 205 934 5562 Schwannomatoisis/Multiple Schwannomas NGS Panel (SCH NG) This testing includes LZTR1, NF2, and SMARCB1 by NGS as well as copy number analysis of LZTR1, NF2, and SMARCB1. An average coverage of 1800x will allow for $2,500 tumor (x2)

Meningiomatosis/Multiple Meningiomas NGS Panel (MEN NG) This testing includes NF2, SMARCB1, SMARCE1, and SUFU by NGS as well as copy number analysis of NF2 and SMARCB1. An average coverage of 1800x will allow for $2,500 tumor Rhabdoid Tumor Predisposition NGS panel (RT NG) This testing includes analysis of SMARCB1 by NGS as well as copy number analysis. An $1,500 tumor average coverage of 1800x will allow for the identification of mosaicism as low as 8% of the alleles. Tuberous Sclerosis Complex NGS panel (TSCP NG) Testing of TSC1 and TSC2 on either blood or fresh/frozen tumor by NGS sequencing and deletion/duplication analysis by MLPA. This testing includes an average coverage of 1800x to allow for NF2 Tumor Comprehensive Testing (NF24) Comprehensive gdna based NF2 testing on a minimum of 2 different tumor specimens by direct sequencing and dosage (del/dup) analysis by MLPA of the NF2 gene. Any mutations found in the tumor tissue will be confirmed in blood at no additional cost if the blood sample is submitted the same week as the tumor specimen. Schwannomatosis Panel (SCHP) Comprehensive DNA based testing for Schwannomatosis and/or mosaic Neurofibromatosis type 2 on a minimum of 2 different tumor block specimens by direct sequencing and dosage (del/dup) analysis by MLPA of the SMARCB1, LZTR1, and NF2 genes. Any mutations found in the tumor tissue will be confirmed in blood at no additional cost if the blood sample is submitted the same week as the tumor specimen. Fresh/Frozen Tumor Based Comprehensive Testing Rhabdoid Tumor Predisposition Syndrome Panel Testing on Fresh/Frozen Tumor Tuberous Sclerosis Complex Testing on Fresh/Frozen Tumor or Affected Tissue $2,500 tumor Tumor Block Based Comprehensive Testing NF2/Schwannomatosis/Meningiomatosis Panel Testing On Tumor Block $1,500 tumor $2,500 tumor (x2) (x2) 81404 Rhabdoid Tumor Predisposition Syndrome Panel Testing on Tumor Block (2) Fresh tumor or affected tissue biopsy, immersed in culture media (1) Tumor block only (2) Blood specimen for confirmation at no additional charge if sent within a week of the tumor specimen (1) Tumor block only (2) Blood specimen for confirmation at no additional charge if sent within a week of the tumor specimen Rhabdoid Tumor Predisposition Testing (SB14RT) This testing includes Sanger sequencing and deletion/duplication analysis by MLPA of SMARCB1. $1,500 tumor 81404 (1) Tumor block only (2) Blood specimen for confirmation at no additional charge if sent within a week of the tumor specimen

Sanger Based Comprehensive Testing NF1/SPRED1 and Other RASopathy Panel Testing NF1/SPRED1 RNA based Comprehensive Study (NFSP R) RNA/cDNA based sequencing and dosage (del/dup) analysis by MLPA and FISH (if a micro deletion is identified) for the NF1 gene in combination with Comprehensive DNA based sequencing and dosage (del/dup) analysis for the SPRED1 gene. For each patient, both NF1 and SPRED1 genes are analyzed comprehensively, but price depends on test result obtained. $2,000 882 (culture) 81404 15 (RUSH) 10 ml of whole blood in EDTA (purple topped) tubes (Minimum of 3 ml for pediatric patients) **Sample must arrive within 60 72hours of collection** Costello syndrome (CST1) DNA based anger sequencing of the HRAS gene VHL Comprehensive (VHL1) DNA based sequencing and dosage (del/dup) analysis by MLPA for the VHL gene. A reduced price is charged if a pathogenic mutation is found during sequencing $0 81404 n/a 15 $650 RASopathy Single Gene Testing Von Hippel Lindau Syndrome $400 (if mutation identified during sequencing) 81404 81403 15 PTEN Related Disorder Testing $1100 PTEN Comprehensive (PTEN1) DNA based testing by sequencing and dosage (del/dup) analysis by MLPA for the $800 (if mutation 81321 81323 15 PTEN gene. A reduced price is charged if a pathogenic mutation is found during identified during sequencing sequencing Known Mutation Testing Options Available for All Genes (1) Minimum of 5 ml whole blood in EDTA (purple topped) tubes (1) Minimum of 5 ml whole blood in EDTA (purple topped) tubes (2) DNA sample (1) Minimum of 5 ml whole blood in EDTA (purple topped) tubes (2) DNA sample Known Mutation (KT2) Targeted detection of a specific, previously known mutation in any gene that is available at our lab by sequence, MLPA, and/or FISH analysis $0 81403 81403 10 Prenatal Testing (PT2) Targeted detection of a specific, previously known, mutation (includes maternal cell contamination (MCC) analysis) $750 81403 81403 6 (1) Direct CVS, (minimum 10 mg pure villi) (2) Direct amniotic fluid (min. 10 ml fluid) (3) 2 T flasks of cultured CVS (>70% confluent) (4) 2 T flasks of cultured amniocytes. (>70% confluent)

RNA based Known Mutation (RT2) RNA based Targeted detection of a specific, previously known mutation in the NF1, NF2, or SMARCB1 gene. $500 **Please note: it is required to contact the laboratory at 205 934 5562 or email medgenomics@uabmc.edu in advance of sending specimens for this testing option** 882 (cultute) 81403 n/a 20 3 6 ml whole blood in EDTA (purple topped) tubes **Sample must arrive within 60 72hours of collection** NGS based Known Mutation (KT2 NG) Next generation sequencing based targeted testing with deep coverage of the alleles. This analysis provides detection of mosaicism for a known mutation present at least 3 5% mutant allele fraction (MAF). 700 n/a Autosomal Recessive Polycystic Kidney Disease PKHD1 ARPKD Comprehensive (PKD1) DNA based sequencing of the entire PKHD1 longest open reading frame and dosage (del/dup) analysis by MLPA, detecting >82% of mutations. This includes automatically reflexing through Tiers 1 3: Tier 1: of 23 exons which will detect 2 clear pathogenic mutations in ~64% of ARPKD patients Tier 2: of the remaining exons of the entire longest open reading frame and targeted analysis for a deep intronic splicing alteration in intron 46 Tier 3: Dosage (del/dup) analysis by MLPA/qPCR A reduced price is charged based on which tiers are necessary to identify two clear pathogenic mutations in a proband. $2600 (Tiers 1+2+3 $2200 (Tiers 1+2 $1100 (only Tier 1 was 81407 n/a n/a 20 8 for Tier 1+2 RUSH (1) 5 ml whole blood in EDTA (purple tubes) (2) biopsy from skin/liver/spleen. (fresh or frozen) (3) 2 T flasks of cultured cells ARPKD (PKDS) DNA based sequencing only of the entire PKHD1 longest open reading frame, detecting ~80% of mutations Tier 1: of 23 exons which will detect 2 clear pathogenic mutations in ~64% of ARPKD patients Tier 2: of the remaining exons of the entire longest open reading frame and targeted analysis for a deep intronic splicing alteration IVS46+653 A>G (Tier 1+2 can be ordered as a standalone test) $2200 (Tiers 1+2 $3200 (for RUSH): $1100 (only Tier 1 is 1 exon: $0 81403 n/a n/a n/a ARPKD Known Mutation (KT2) Targeted detection of specific, previously known, PKHD1 mutation(s) in family members by sequence and/or MLPA analysis 2 exons: $340 81403(x2) n/a 15 (1) 5 ml whole blood in EDTA (purple topped) tubes (2) Buccal swab sample MLPA: $0 n/a MLPA: 81407

ARPKD Prenatal Targeted (PT2) Targeted detection of specific, previously known, PKHD1 mutations (includes maternal cell contamination (MCC) analysis) $1,000 81403(x2) 81403(x2) 6 (1) Direct CVS, (minimum 10 mg pure villi) (2) Direct amniotic fluid (min. 10 ml fluid) (3) 2 T flasks of cultured CVS (>70% confluent) (4) 2 T flasks of cultured amniocytes. (>70% confluent) ARPKD Informativity (PKDL) Haplotype analysis by PCR of 7 markers within and flanking the PKHD1 disease interval on chromosome 6p21 cen ARPKD Prenatal Linkage (PKDPL) Haplotype analysis by PCR of 7 markers within and flanking the PKHD1 disease interval on chromosome 6p21 cen as a prenatal test (includes maternal cell contamination (MCC) analysis) $400/ individual tested n/a 81265 20 $500/ individual tested n/a 81265 6 Please send samples from the parents and their children for informativity results (1) 10ml of whole blood in EDTA (purple topped) tubes. (2 ml minimum for pediatric patients) (2) Paraffin embedded tissue blocks or whole tissue from affected individual (3) For prenatal samples, please send 2 T flasks of cultured CVS or 2 T flasks of cultured amniocytes Please also send 1 5 ml of blood or buccal swab sample from mother for maternal contamination studies.